Effects of intranasal versus oral hormone therapy on asymmetric dimethylarginine in healthy postmenopausal women: A randomized study

Atherosclerosis

Volumn 195, Issue 1, 2007, Pages 181-188

  Verhoeven, Marieke O ^a   Hemelaar, Majoie ^a   Teerlink, Tom ^a   Kenemans, Peter ^a   van der Mooren, Marius J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ADMA; Arginine; Asymmetric dimethylarginine; Estradiol; Intranasal; Norethisterone (acetate); Postmenopausal; Symmetric dimethylarginine

Indexed keywords

ARGININE; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NORETHISTERONE ACETATE; S 21405; SYMMETRIC DIMETHYLARGININE; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONAL THERAPY; HUMAN; MODULATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYNTHESIS; THERAPY EFFECT;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; AGED; ARGININE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; NORETHINDRONE; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 35248885626     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.09.018     Document Type: Article

References (33)

1. Barrett-Connor E. Fortnightly review: hormone replacement therapy. BMJ 317 (1998) 457-461
2. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280 (1998) 605-613
3. Manson J.E., Hsia J., Johnson K.C., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349 (2003) 523-534
4. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 20 Suppl 12 (1992) S60-S62
5. Zoccali C., Bode-Böger S.M., Mallamaci F., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358 (2001) 2113-2117
6. Valkonen V.P., Päivä H., Salonen J.T., et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358 (2001) 2127-2128
7. Nijveldt R.J., Teerlink T., van der Hoven B., et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 22 (2003) 23-30
8. Schnabel R., Blankenberg S., Lubos E., et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 97 (2005) e53-e59
9. Li X.P., Zhou Y., Zhao S.P., et al. Effect of endogenous estrogen on endothelial function in women with coronary heart disease and its mechanism. Clin Chim Acta 339 (2004) 183-188
10. Teerlink T., Neele S.J.M., de Jong S., Netelenbos J.C., and Stehouwer C.D.A. Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women. Clin Sci 105 (2003) 67-71
11. Post M.S., Verhoeven M.O., van der Mooren M.J., et al. Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women. J Clin Endocrinol Metab 88 (2003) 4221-4226
12. Verhoeven M.O., Hemelaar M., van der Mooren M.J., Kenemans P., and Teerlink T. Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study. J Intern Med 259 (2006) 199-208
13. Aerodiol Study Group, Studd J., Pornel B., Marton I., et al. Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Lancet 353 (1999) 1574-1578
14. Mattsson L.A., Christiansen C., Colau J.C., et al. Clinical equivalence of intranasal and oral 17β-estradiol for postmenopausal symptoms. Am J Obstet Gynecol 182 (2000) 545-552
15. Hemelaar M., Kenemans P., de Bie L., van de Weijer P.H., and van der Mooren M.J. Intranasal continuous combined 17β-estradiol/norethisterone therapy improves the lipid profile in healthy postmenopausal women. Fertil Steril 85 (2006) 979-988
16. Hemelaar M., Kenemans P., Schalkwijk C.G., Braat D.D., and van der Mooren M.J. No increase in C-reactive protein levels during intranasal compared to oral hormone therapy in healthy post-menopausal women. Hum Reprod 21 (2006) 1635-1642
17. Bode-Böger S.M., Böger R.H., Kienke S., Junker W., and Frölich J.C. Elevated l-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary l-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 219 (1996) 598-603
18. Hemelaar M., Rosing J., Kenemans P., et al. Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women. Arterioscler Thromb Vasc Biol 26 (2006) 1660-1666
19. Devissaguet J.P., Brion N., Lhote O., and Deloffre P. Pulsed estrogen therapy: pharmacokinetics of intranasal 17-beta-estradiol (S21400) in postmenopausal women and comparison with oral and transdermal formulations. Eur J Drug Metab Pharmacokinet 24 (1999) 265-271
20. S 21405 Investigator's Brochure. version no 3. 22-2-2001; Institut de Recherches Internationales Servier, Courbevoie, France.
21. De Jong S., and Teerlink T. Analysis of asymmetric dimethylarginine in plasma by HPLC using a monolithic column. Anal Biochem 353 (2006) 287-289
22. Teerlink T. Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance. Clin Chem Lab Med 43 (2005) 1130-1138
23. Achan V., Broadhead M., Malaki M., et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23 (2003) 1455-1459
24. Nijveldt R.J., Teerlink T., Siroen M.P.C., et al. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin Nutr 22 (2003) 17-22
25. Siroen M.P.C., Warlé M.C., Teerlink T., et al. The transplanted liver graft is capable of clearing asymmetric dimethylarginine. Liver Transpl 10 (2004) 1524-1530
26. Teerlink T. ADMA metabolism and clearance. Vasc Med 10 Suppl. (2005) S73-S81
27. Kenemans P., Genazzani A.R., Palacios S., and Schneider H.P.G. Pulsed estrogen exposure selectively modulates tissue response: a hypothesis. Gynecol Endocrinol 18 (2004) 159-164
28. Sitruk-Ware R. Progestins and cardiovascular risk markers. Steroids 65 (2000) 651-658
29. G-dimethyl-l-arginine in 500 subjects. Eur J Clin Invest 35 (2005) 622-626
30. Goonasekera C.D.A., Shah V., Rees D.D., and Dillon M.J. Vascular endothelial cell activation associated with increased plasma asymmetric dimethyl arginine in children and young adults with hypertension: a basis for atheroma?. Blood Press 9 (2000) 16-21
31. Schnog J.B., Teerlink T., van der Dijs F.P.L., Duits A.J., and Muskiet F.A.J. Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease. Ann Hematol 84 (2005) 282-286
32. Tsao P.S., Lewis N.P., Alpert S., and Cooke J.P. Exposure to shear stress alters endothelial adhesiveness. Role of nitric oxide. Circulation 92 (1995) 3513-3519
33. Böger R.H., Bode-Böger S.M., Tsao P.S., et al. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 36 (2000) 2287-2295